VIDEO: New treatment demonstrates 'significant progress' in geographic atrophy care

Editor’s note: This is an automatically generated transcript, which has been slightly edited for clarity. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.

For the first time ever, we’ve finally made some significant progress in managing geographic atrophy. Up until 2023, there have been no treatments that have been ever shown to be beneficial and therefore available for us to use to treat geographic atrophy. But this year, we had the FDA approval of pegcetacoplan (Syfovre, Apellis Pharmaceuticals), a complement blocker that was shown to decrease the rate of growth of geographic atrophy over 1 to 2 years, and that’s a major advance. The effect in slowing the growth is somewhat modest. It doesn’t stop it. It certainly doesn’t reverse it. But nonetheless, to slow GA growth is a big step forward in our ability to manage geographic atrophy.